Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03578887 · ClinicalTrials.gov registry record · NA
A Cohort Study of Weight Loss and Gliosis
A NA study of Obesity, Gliosis, Weight-Loss, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 112
- Enrollment target
- 1
- Study location
NCT03578887: Completed NA study of Obesity, Gliosis, Weight-Loss, sponsored by University of Washington.
NCT03578887 is a NA study of Obesity, Gliosis, Weight-Loss that has completed, run by University of Washington. The registered enrollment target is 112 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03578887, a NA study of Obesity, Gliosis, Weight-Loss, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 112 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients and clinicians need better options to prevent the weight regain that almost universally follows a weight loss intervention. In lay terms, a new, higher "set point" seems to occur after people gain weight. Evidence from some research studies reinforces these observations, showing that processes of energy homeostasis vigorously defend the higher level of adiposity for years, if not permanently. Only bariatric surgery appears to "re-set" to a lower level of adiposity. No clear mechanism has been elucidated to date that explains these phenomena. The current proposal endeavors to address this crucial scientific gap by translating preclinical data into human studies testing novel mechanistic hypotheses. Prior studies in rodents show that a high-fat diet causes inflammation and a cellular response, known as gliosis, within hypothalamic regions regulating energy balance and glucose homeostasis. Evidence further suggests that gliosis might play a pathogenic role in obesity and type 2 diabetes mellitus (T2D) because its development precedes weight gain and impaired glucose homeostasis and its inhibition improves metabolic health. Importantly, gliosis is detectable in mice and humans by magnetic resonance imaging (MRI). Using MRI, the investigators discovered the first evidence of gliosis in obese humans and went on to show associations of gliosis with insulin resistance in humans, independent of the level of adiposity. New findings suggest that people with T2D have more extensive gliosis than is seen in nondiabetic obese subjects. Further findings reveal that gliosis improves, but is not completely reversed, 8 mo. after Roux-en-Y gastric bypass (RYGB) surgery in T2D patients. It remains unknown whether gliosis improves similarly when weight loss occurs by lifestyle change or if the efficacy and durability of weight loss via bariatric surgery is partially explained by its ability to reverse gliosis via an as yet unknown mechanism of action. We therefore propose three
Conditions Studied
Interventions
- BEHAVIORAL Behavioral Weight Loss Program
- PROCEDURE Roux-en-Y Gastric Bypass or Sleeve Gastrectomy
Study Locations (1)
Washington
- University of Washington - South Lake Union - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2019-06-01 |
| Est. Completion | 2025-06-30 |
| Phase | NA |
What the finished NCT03578887 record still lists
NCT03578887 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Obesity, Gliosis, Weight-Loss appearing as the primary indexed condition, and to 2 interventions - of which Behavioral Weight Loss Program is the first listed.
NCT03578887 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT03578887 about?
NCT03578887 is a clinical study titled "A Cohort Study of Weight Loss and Gliosis". Patients and clinicians need better options to prevent the weight regain that almost universally follows a weight loss intervention. In lay terms, a new, higher "set point" seems to occur after people gain weight. Evidence from some research studies reinforces these observations, showing that proces...
What is the current status of trial NCT03578887?
This trial is currently completed. It is a NA study. The enrollment target is 112 participants. The study started on 2019-06-01. Estimated completion is 2025-06-30.
What conditions does trial NCT03578887 study?
This clinical trial studies the following conditions: Obesity, Gliosis, Weight-Loss.
What interventions are being tested in trial NCT03578887?
The interventions under investigation include: Behavioral Weight Loss Program (BEHAVIORAL), Roux-en-Y Gastric Bypass or Sleeve Gastrectomy (PROCEDURE).
Who is sponsoring clinical trial NCT03578887?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03578887 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03578887's enrollment target sits among peer trials
112 813th of 2000 higher than 1,185 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI